Evidence map›Paper›PMID 32845306›Full record

ArticleThe Journal of infectious diseases2020

Reply to Hasford and to Spinola et al.

Nir Eyal, Marc Lipsitch, Peter G Smith

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Nir EyalCenter for Population-Level Bioethics, Rutgers University, New Brunswick, New Jersey, USA.
Marc LipsitchCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Peter G SmithMRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.

Funding

Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIPSITCH, MARC · 2009 to 2018
$26.4M
HIV cure studies: risk, risk perception, and ethicsR01AI114617 · NIAID · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI EYAL, NIR · 2015 to 2018
$3.2M
HIV cure studies: risk, risk perception, and ethicsR56AI114617 · NIAID · HARVARD MEDICAL SCHOOL · PI EYAL, NIR · 2014 to 2014
$528k
Medical Research Council MR/R010161/1NIAID NIH HHS R01 AI114617NIAID NIH HHS R56 AI114617NIGMS NIH HHS U54 GM088558
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CoronavirusCOVID-19 VaccinesHumansLicensureVaccinationCOVID-19 Vaccines

Identifiers

PMID32845306
PMCPMC7529012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.